Bradycor bradykinin antagonist: CRTQ announced it will not resume Phase II trials of Bradycor until it finds a corporate partner. CRTQ halted the trials in July

Cortech Inc. (CRTQ), Denver Product: Bradycor bradykinin antagonist Indication: Traumatic brain injury and systemic inflammatory response syndrome Status: CRTQ announced it will not resume Phase II tr...